Revenue growth 9%+ across all segments, AST margin profile strong. Target $290 vs current $217 = +33.6% upside. Thesis solid but no identifiable near-term catalyst — missing the one element for conv 8.
Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
25.8%/yr
±6.5% · revenue growth to justify current price
FCF-Based Reverse DCF
19.8%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
STE: Broad-based 9% revenue growth (all segments positive) but Q3 gross margin down 70 bps due to tariffs/inflation despite pricing wins. AST performing best (45% margins); Healthcare/Life Sciences fa...